In cellular immunoblot assays, gilteritinib inhibited FLT3 phosphorylation with IC50 values of 5 nM in wild-type FLT3-expressing SEMK2 cells and 1.8 nM in FLT3-ITD-expressing Molm14 cells. The Ba/F3 FLT3-ITD/F691L model had a higher IC50 of 12.2 nM, indicating reduced potency in that model. These values measure receptor phosphorylation, not cell viability. [2]
In normal-donor bone marrow colony assays, gilteritinib preserved CFU-GM and BFU-E recovery more strongly than quizartinib over the displayed 0–200 nM range, with some reduction at higher concentrations. This ex vivo result does not establish freedom from clinical myelosuppression. [2]
Cell-free tyrosine kinase inhibition
Biochemical assay · Cell-free tyrosine kinase assays [1]
FLT3 and AXL inhibition was stronger than c-KIT inhibition, with activity also detected against LTK and EML4-ALK. These biochemical values do not establish cellular selectivity or the contribution of AXL to antitumor effects.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response assays; initial 78-kinase screen at 1 and 5 nM.
- Method
- Cell-free kinase inhibition; three individual IC50 experiments per kinase.
- Vehicle
- DMSO for in vitro compounds (shared materials).
- Reported limits
- Exact concentration series and incubation duration are not specified in the acquired main-text kinase methods. No cellular treatment exposure inferred.
Methods and source locations
Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib hemifumarate
Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.
Materials and methods: Compounds and Kinase inhibitory assays; Results: Gilteritinib inhibitory activity; Table 1
FLT3 kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)
AXL kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)
LTK kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)
EML4-ALK kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)
c-KIT kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)
Cellular FLT3 phosphorylation across receptor subtypes
Cell-based study · SEMK2 wild-type FLT3, Molm14 FLT3-ITD, and Ba/F3 cells bearing defined FLT3 variants [2]
Gilteritinib inhibited FLT3 phosphorylation at low nanomolar concentrations in these cellular models. The ITD/F691L model required a higher concentration than the other listed variants; phosphorylation IC50 is distinct from cell-viability IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Increasing ASP2215 concentrations; IC50 values are endpoints, not administered doses.
- Exposure duration
- 1 hour
- Method
- Cell incubation in RPMI/10% FBS, followed by phospho-/total-FLT3 immunoprecipitation/immunoblot and densitometry.
- Reported limits
- Exact titration range, solvent and replicate count not established from acquired main text; supplemental methods not retrieved.
Methods and source locations
Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib / ASP2215; salt form not established from acquired main text
Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.
Main text receptor-inhibition paragraph; Figure 1A and caption
SEMK2, wild-type FLT3 phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Molm14, FLT3-ITD phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Ba/F3, FLT3-D835Y phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Ba/F3, FLT3-D835H phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Ba/F3, FLT3-D835V phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Ba/F3, FLT3-ITD/F691L phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph
Normal-donor hematopoietic colony formation
Cell-based study · Mononuclear cells from normal human donor bone marrow [2]
Relative to the zero-drug baseline, gilteritinib preserved colony recovery more strongly than quizartinib over the displayed concentration range. Recovery was not completely preserved at the highest concentrations. This ex vivo observation does not demonstrate clinical absence of myelosuppression.
Literature-Reported Treatment Conditions
- Treatment concentration
- Gilteritinib or quizartinib: 0, 10, 20, 50, 100 and 200 nM (Fig. 2B).
- Exposure duration
- 10–12 days
- Method
- Normal-donor bone marrow mononuclear cells plated at 10^5 cells/mL in MethoCult; CFU-GM and BFU-E counted.
- Co-treatment
- None; gilteritinib and quizartinib tested separately.
- Reported limits
- Solvent, donor count and precise n semantics not established in the acquired caption/main text; supplemental methods not retrieved.
Methods and source locations
Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib / ASP2215; salt form not established from acquired main text
Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.
Main text c-Kit/hematopoiesis paragraph; Figure 2B and caption
CFU-GM and BFU-E clonogenic recovery: Colony counts after 10–12 days; Figure 2B viewed. No exact percentages inferred from bars; caption does not define whether n = 3 denotes donors or other replicates. — Figure 2B, caption and adjacent main-text c-Kit paragraph